Researchers identify new therapeutic target in advanced gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common type of sarcoma, often driven by mutations in the KIT or PDGFRA genes. Tyrosine kinase inhibitors (TKIs) like imatinib have been the cornerstone of treatment, but most patients eventually develop resistance due to secondary mutations, leading to disease progression and limited survival.

👉 Full Story